Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRIP1 T997Rfs*61 |
| Therapy | Olaparib |
| Indication/Tumor Type | pancreatic adenocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRIP1 T997Rfs*61 | pancreatic adenocarcinoma | predicted - sensitive | Olaparib | Case Reports/Case Series | Actionable | In a Phase II trial, treatment with Lynparza (olaparib) resulted in 2 responders and 2 prolonged stable disease in 8 advanced solid tumor patients harboring BRIP1 mutations, including a partial response in a patient with pancreatic adenocarcinoma harboring BRIP1 T997Rfs*61 (reported as c.2990_2993del) (PMID: 42105598). | 42105598 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (42105598) | Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2. | Full reference... |